SINGAPORE, May 29 /PRNewswire/ -- S*BIO Pte Ltd, a privately held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer, has entered into a two-year research partnership with National University Hospital-National University of Singapore Tissue Repository (NUH-NUS TR). The company is partnering with Dr. Robert Hewitt, Director of the NUH-NUS TR, to conduct biomarker research and evaluate tumors' responsiveness to S*BIO's proprietary anti-cancer compounds.
"This partnership will allow us to better understand our compounds and their effects before being used in a clinical setting," said Dr. Jan-Anders Karlsson, CEO of S*BIO. "Dr. Hewitt brings a wealth of experience to our program. NUH-NUS TR provides us with valuable DNA/RNA samples and primary cell lines from numerous tumor types."
"We believe that combining S*BIO's technology and NUH-NUS TR's high quality and well-documented biomaterials will enable us to make significant progress in the discovery of new compounds to treat cancer," said Dr. Hewitt.
Dr. Hewitt holds a medical degree from the University of London and a Ph.D. from the University of Glasgow. He is currently Assistant Professor at the Department of Pathology, NUS Yong Loo Lin School of Medicine and Senior Research Scientist of the Oncology Research Institute at NUS. Dr. Hewitt's research interests include invasion and metastasis of tumors, desmoplastic reaction, proteases and extracellular matrix and tumor suppression genes.
About NUH-NUS TR
The NUH-NUS TR is funded by National University Hospital (NUH), National University of Singapore (NUS) and the Singapore Cancer Syndicate (SCS). It has a multidisciplinary team of 20 staff including a pathologist, molecular biologists, cancer registrars, technologists, nurses and informatics experts. It provides researchers with high quality and well documented biomaterials in a variety of formats. These biomaterials may be derived from cancer or non- cancer tissue.
About S*BIO Pte Ltd
S*BIO is a privately held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO is aggressively building a pipeline of internal and in-licensed compounds. Its lead candidate, SB939, has entered clinical trials.
In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong linkages with a network of medical oncologists in Asia Pacific. More information about S*BIO can be found at http://www.sbio.com.
S*BIO Pte Ltd: Stephen Keith Rhind, Ph.D. Senior Vice President, Corporate Development Tel: +65 6827 5000 (Singapore) stephen_rhind@sbio.com Chan Yiu Lin PR Consultant Tel: +65 97655897 (Singapore) pr@sbio.com Russo Partners, LLC: Tony Russo +1 212-845-4251 tony.russo@russopartnersllc.com Andreas Marathovouniotis +1 212-845-4253 andreas.marathis@russopartnersllc.com
S*BIO Pte LtdCONTACT: Stephen Keith Rhind, Ph.D. of Senior Vice President, CorporateDevelopment, +65 6827 5000 (Singapore), stephen_rhind@sbio.com, or Chan YiuLin, PR Consultant, +65 97655897 (Singapore), pr@sbio.com, both of S*BIOPte Ltd; or Tony Russo, +1-212-845-4251, tony.russo@russopartnersllc.com,or Andreas Marathovouniotis, +1-212-845-4253,andreas.marathis@russopartnersllc.com, both of Russo Partners, LLC, forS*BIO Pte Ltd
Web site: http://www.sbio.com/
